Monoclonal gammopathy of undetermined significance (MGUS) occurs in 4% of the population over 50 years old and represents a precursor lesion to myeloma. Although several studies have examined the immune response to antigens in human cancer including myeloma, the nature of immune response against preneoplastic lesions is less studied. This application builds on our recent findings that a large proportion of patients with MGUS harbor spontaneous immune responses against antigens expressed on embryonal / cancer stem cells. In preliminary studies, the detection of these responses predicted reduced probability of disease progression. The specific objectives of the studies in this application are 1) to better understand this naturally occurring immune response in MGUS;2) to further evaluate the basis of the absence of these responses in myeloma patients;and 3) to understand the clinical and prognostic significance of immunity to stem cell antigens in these patients in the context of a prospective clinical trial. These studies have direct implications for approaches to boost host immunity against myeloma stem cells and harnessing properties of host response for risk assessment and early detection of cancer.

Public Health Relevance

The goal of these studies is to understand the properties of naturally occurring immune responses against cancer stem cells in people without cancer. Harnessing such responses may be important for prevention of cancer, such as myeloma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA135110-06
Application #
8511182
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Jessup, John M
Project Start
2008-09-15
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
6
Fiscal Year
2013
Total Cost
$268,604
Indirect Cost
$106,305
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sehgal, Kartik; Ragheb, Ragy; Fahmy, Tarek M et al. (2014) Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol 193:2297-305
Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85
Zhao, S; Choi, M; Heuck, C et al. (2014) Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28:1548-52
Sehgal, Kartik; Dhodapkar, Kavita M; Dhodapkar, Madhav V (2014) Targeting human dendritic cells in situ to improve vaccines. Immunol Lett 162:59-67
Dhodapkar, Madhav V (2013) Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right? Cancer Prev Res (Phila) 6:173-6
Richter, Joshua; Neparidze, Natalia; Zhang, Lin et al. (2013) Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121:423-30
Dhodapkar, Madhav V; Dhodapkar, Kavita M (2011) Vaccines targeting cancer stem cells: are they within reach? Cancer J 17:397-402
Dhodapkar, Kavita M; Feldman, Darren; Matthews, Phillip et al. (2010) Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 107:8718-23
Dhodapkar, Madhav V (2010) Immunity to stemness genes in human cancer. Curr Opin Immunol 22:245-50
Kukreja, Anjli; Radfar, Soroosh; Sun, Ben-Hua et al. (2009) Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 114:3413-21

Showing the most recent 10 out of 15 publications